Evidence mapPaperPMID 42041639Full record

ArticleDiseases (Basel, Switzerland)2026

Towards a Better Understanding of MASLD: Patient Health Literacy, Illness Perception, and Awareness.

Irini Gergianaki, Foteini Anastasiou, Sophia Papadakis, Marilena Anastasaki, Manolis Linardakis, Juan Mendive, Leen J M Heyens, Ger Koek, Jean Muris, Christos Lionis

Abstract read
In one paragraph

Article in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Irini GergianakiClinic of Social and Family Medicine, School of Medicine, University of Crete, 70013 Heraklion, Crete, Greece.
Foteini Anastasiou4th Local Primary Health Care Team, 71303 Heraklion, Crete, Greece.
Sophia PapadakisClinic of Social and Family Medicine, School of Medicine, University of Crete, 70013 Heraklion, Crete, Greece.
Marilena AnastasakiClinic of Social and Family Medicine, School of Medicine, University of Crete, 70013 Heraklion, Crete, Greece.ORCID 0000-0003-2306-1626
Manolis LinardakisClinic of Social and Family Medicine, School of Medicine, University of Crete, 70013 Heraklion, Crete, Greece.ORCID 0000-0003-3849-3907
Juan MendiveEuropean Society for Primary Care Gastroenterology, London E1 6HU, UK.ORCID 0000-0001-8095-7707
Leen J M HeyensFaculty of Health and Life Sciences, Hasselt University, 3500 Hasselt, Belgium.ORCID 0000-0003-4850-6011
Ger KoekSchool of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, 6211 LK Maastricht, The Netherlands.
Jean MurisEuropean Society for Primary Care Gastroenterology, London E1 6HU, UK.ORCID 0000-0002-8780-476X
Christos LionisClinic of Social and Family Medicine, School of Medicine, University of Crete, 70013 Heraklion, Crete, Greece.ORCID 0000-0002-9324-2839

Funding

Gilead Sciences (United States) IN-EU989-5753
6 · The paper itself

Abstract

objectivesThe objective of this study was to investigate metabolic dysfunction-associated steatotic liver disease (MASLD)-related awareness, health literacy (HL), and illness perception among patients at risk of MASLD in European primary care settings.

methodsParticipants aged ≥50 years with either obesity, metabolic syndrome (MetS), or type 2 diabetes mellitus (T2DM), and attending general practices (GPs) in Greece, Spain, or The Netherlands were included in the study. The participants completed surveys to collect data on their socio-demographic characteristics and health habits, including the European Health Literacy Survey (HLS-E-Q16), the Brief Illness Perception Questionnaire [B-IPQ], and the Public Awareness of NAFLD Questionnaire.

resultsOverall, 234 patients participated in the study (mean age: 66.5 ± 9.5 years; 45.7% were male). Among the participants, 64.5%, 66.2%, and 59.8% had a diagnosis of diabetes, obesity, and MetS, respectively. Almost one-third (27.9%) had never heard about MASLD or discussed MASLD with their GP. Twelve percent (12.1%) had never heard about cirrhosis, and 20.5% were unaware that liver disorders may cause serious health problems. Overall, 43.6% of the patients had a sufficient level of HL (score >13) with a mean score of 11.5 ± 3.3. Illness perception (B-IPQ score) was low at 41.6 ± 11.6. Significantly higher B-IPQ scores were documented for female compared to male respondents (43.1 vs. 39.8;

conclusionsDespite being at risk, a significant proportion of the study participants were unaware of MASLD, its risk factors, and their personal susceptibility. This study underscores the importance of enhancing patient HL and promoting prevention and risk reduction, particularly among high-risk patient populations.

Indexed as

Europegeneral practiceGreecehealth literacyMASLDprimary careSpainThe Netherlands

Identifiers

PMID42041639
PMCPMC13115058

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.